Form 4: Ideaya Biosciences Executive Acquires Stock Options

Andres Ruiz Briseno, SVP, Head of Finance and Investor Relations at Ideaya Biosciences, acquired stock options for 85,000 shares on March 1, 2024.

Summary

• Andres Ruiz Briseno, an executive at Ideaya Biosciences, Inc., filed a Form 4 indicating a change in beneficial ownership.
• On March 1, 2024, Briseno acquired stock options for 85,000 shares of Ideaya Biosciences common stock at an exercise price of $46.22.
• The options vest over four years, starting with 25% vesting on the first anniversary of January 1, 2024, and the remainder vesting monthly thereafter.
• Following the transaction, Briseno directly owns options for 85,000 shares.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It reports a standard transaction (stock option grant) without any explicit positive or negative implications.

Positives

• The acquisition of stock options by a high-ranking executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of the US financial market, providing transparency into the transactions of company insiders. This filing indicates a standard executive compensation practice.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use stock options as part of their compensation packages to align executive interests with shareholder value.
• The vesting schedule described is fairly standard, aligning with typical industry practices for retaining key personnel.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of executive confidence.

Key Dates